Sort   by:  
 Page size 
UnknownExtended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Not available
S-EPMC10521424 | biostudies-literature
UnknownAssociation of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Not available
S-EPMC6439730 | biostudies-literature
UnknownValidation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects.
Not available
S-EPMC6704046 | biostudies-literature
UnknownCortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.
Not available
S-EPMC11752103 | biostudies-literature
UnknownThe spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
Not available
S-EPMC10300577 | biostudies-literature
UnknownAssessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis.
Not available
S-EPMC10503816 | biostudies-literature
UnknownDigital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
Not available
S-EPMC11377687 | biostudies-literature
UnknownA multidisciplinary neuro-oncological triage panel reduces the time to referral and treatment for patients with a brain tumor.
Not available
S-EPMC8475234 | biostudies-literature
UnknownEfficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Not available
S-EPMC7447657 | biostudies-literature
UnknownDiscontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Not available
S-EPMC11811793 | biostudies-literature
Sort   by:  
 Page size